In vitro Effectiveness of Lecithin-Containing Antibiotic Lock Solutions on Klebsiella pneumoniae Biofilms

Abstract

Aim: Klebsiella pneumoniae which is a gram negative, generally capsulated, non-moving, non-sporing bacteria, nowadays to be an important cause of community-acquired and nosocomial infection. These bacteria can cause catheter related infections by forming biofilm on the surface of catheter. The most effective treatment method of catheter related infection is to remove infectious catheter and start systemic antibiotic treatment but this process can't be practiced in all cases due to the patients’ health conditions. Infectious Diseases Society of America and Centers for Disease Control and Prevention suggest that systemic antibiotic therapy together with antibiotic lock therapy (ALT), as an adjuvant therapy, for patients whose infectious catheter can't be removed.

Material and Methods: In our study, the in vitro efficacy of several antibiotics alone or in combination with lecithin which is a surface active agent, as a 96 hour lock solution on in vitro CVC biofilm model against two biofilm-embedded catheter related bacteremia infection agents Klebsiella pneumoniae strains were investigated.

Results: According to our results, ALT solutions containing lecithin+tobramycin and lecithin+doripenem combinations had an antagonist effect on the biofilm-embedded strains by increasing at least 2-log₁₀ in both strains and ALT solutions containing lecithin+colistin, lecithin+tigecycline and lecithin+ciprofloxacin had less effect than antibiotics alone on the biofilm-embedded strains.

Conclusion: In our study, we believe that because lecithin+tobramycin and lecithin+doripenem combinations showed antagonist activity, the usage of lecithin in daily life as a nutritional supplement will be a guide for clinicians.

Keywords

• Catheter infections,biofilm,antimicrobial lock therapy,lecithin,Klebsiella pneumoniae

Lesitin İçeren Antibiyotik Kilit Çözeltilerinin Klebsiella pneumoniae Biyofilmi Üzerine in vitro Etkileri

Abstract

Amaç: Gram negatif, genellikle kapsüllü, hareketsiz, sporsuz, çomak şeklinde bir bakteri olan Klebsiella pneumoniae günümüzde toplum ve hastane kökenli enfeksiyonların önemli etkenlerinden biridir. Bu bakteri kateter yüzeyinde bir mikrobiyal biyofilm oluşturarak kateter ilişkili enfeksiyonlara neden olabilmektedir. Kateter ilişkili enfeksiyonların tedavisinde en etkili tedavi yöntemi enfekte kateteri çıkarmak ve sistemik antibiyotik tedavisine başlamak olsa da bu işlem hastanın sağlık durumu ile ilgili nedenlerle her zaman yapılamamaktadır. Enfekte kateterin çıkartılamadığı hastalarda sistemik antimikrobiyal tedavi ile birlikte yardımcı bir tedavi seçeneği olarak antibiyotik kilit (AK) tedavisi kullanılması Infectious Diseases Society of America ve Centers for Disease Control and Prevention gibi sağlık kuruluşları tarafından önerilmektedir.

Gereç ve Yöntemler: Çalışmamızda, in vitro yöntemle santral venöz kateter (SVK) modeli oluşturularak biyofilm oluşturduğu tespit edilen iki SVK ilişkili bakteriyemi enfeksiyon etkeni Klebsiella pneumoniae suşuna karşı bir yüzey aktif ajan olan lesitinin tek başına ve çeşitli antibiyotiklerle kombinasyonlarının 96 saatlik etkisi araştırılmıştır.

Bulgular: Çalışmamızdan elde ettiğimiz sonuçlara göre, lesitin+tobramisin ve lesitin+doripenem kombinasyonlarını içeren AK çözeltisinin her iki suş içinde en az 2-log₁₀’luk bir artış sağlayarak biyofilme gömülmüş suşlar üzerinde antagonist etki oluşturduğu, lesitin+kolistin, lesitin+tigesiklin ve lesitin+siprofloksasin içeren AK çözeltilerinin ise her iki suşa ait kateter biyofilm modelinde antibiyotiklerin tek başına oluşturduğu etkiden daha az etki gösterdiği saptanmıştır.

Sonuç: Çalışmamızda lesitin+tobramisin ve lesitin+doripenem kombinasyonlarının antagonist etki göstermesi günlük hayatta tükettiğimiz pek çok üründe gıda takviyesi olarak bulunan lesitinin enfeksiyon hastalıklarının tedavisindeki etkilerinin ortaya koyulması açısından önemli olduğu düşüncesindeyiz.

Keywords

• Kateter enfeksiyonları,biyofilm,antibiyotik kilit tedavisi,lesitin,Klebsiella pneumoniae

References

1. 1. Donlan RM. Biofilms on central venous catheters: is eradication possible? Curr Topics Microbiol Immunol. 2008; 322: 133-61.
2. 2. Lee MY, Ko KS, Song JH. In vitro effectiveness of the antimicrobial lock technique (ALT) for the treatment of catheter-related infections by Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob Chemother. 2007; 60(4): 782-7. https://doi.org/10.1093/jac/dkm295.
3. 3. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284(5418): 1318-22. doi: 10.1126/science.284.5418.1318.
4. 4. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter related infection: 2009 update by the infectious diseases society of America. IDSA Guidelines for intravascular catheter related infection. Clin Infect Dis. 2009; 49(1): 1-45. doi: 10.1086/599376.
5. 5. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother. 2007; 51(1): 78-83. doi:10.1128/AAC.00154-06.
6. 6. Epa.gov [Internet]. Washington, DC, USA: US Environmental Protection Agency Office of Pesticide Programs, Office of Pesticide Programs Microbiology Laboratory Environmental Science Center, Ft. Meade, MD [Updated: 2016 Nov 08; Cited: 2019 Apr 5]. Available from: https://www.epa.gov/sites/production/files/2016-08/documents/mb-05-14.pdf.
7. 7. Mataracı Kara E, Özbek Çelik B. Investigation of the effects of various antibiotics against Klebsiella pneumoniae biofilms on in vitro catheter model. Journal of Chemotherapy. 2018; 30(2): 82-8. doi: 10.1080/1120009X.2017.1390633.
8. 8. Raad II, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis. 2007; 7(10): 645-57. https://doi.org/10.1016/S1473-3099(07)70235-9.

9. 9. en-standard.eu [Internet]. Czech Republic: European Standard Store [Updated: 2018 May 15; Cited: 2019 Apr 5]. Available from: https://www.en-standard.eu/18-30373116-dc-bs-en-1276-chemical-disinfectants-and-antiseptics-quantitative-suspension-test-for-the-evaluation-of-bactericidal-activity-of-chemical-disinfectants-and-antiseptics-used-in-food-industrial-domestic-and-institutional-areas-test-method-and-re/.
10. 10. Singh VK, Pandey PM, Agarwal T, Kumar D, Banerjee I, Anis A, et al. Development of soy lecithin based novel self-assembled emulsion hydrogels. J Mechanical Behavior of Biomedical Materials. 2016; 55: 250-63. doi: 10.1016/j.jmbbm.2015.10.027.
11. 11. pharmacopeia.cn [Internet]. USA: The United States Pharmacopeia [Updated: 2008 May 15; Cited: 2019 Mar 1]. Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1227.html.
12. 12. Aumeran C, Thibert E, Chapelle FA, Hennequin C, Lesens O, Traore O. Assessment on experimental bacterial biofilms and clinical practice of the efficacy of sampling solutions for microbiological testing of endoscopes. J Clin Microbiol. 2012; 50(3): 938-42. doi: 10.1128/JCM.06221-11.
13. 13. Kumon H, Hashimoto H, Nishimura M, Monden K, Ono N. Catheter-associated urinary tract infections: impact of catheter materials on their management. Int J Antimicrob Agents. 2001; 17: 311-6. https://doi.org/10.1016/S0924-8579(00)00360-5.
14. 14. eucast.org [Internet]. Basel Switzerland: European Society of Clinical Microbiology and Infectious Diseases [Updated: 2019 Jan 1; Cited: 2019 Apr 1]. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf.
15. 15. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 2000; 40(2): 175-9. https://doi.org/10.1016/S0167-7012(00)00122-6.
16. 16. clsi.org [Internet]. Wayne, PA: Clinical and Laboratory Standards Institute [Updated: 1999 Sep 1; Cited: 2019 Mar 1]. Available from: https://clsi.org/standards/products/microbiology/documents/m26/.
17. 17. Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. Infect Drug Resist. 2014; 7: 343-63. doi: 10.2147/IDR.S51388.
18. 18. Özbek Çelik B, Mataraci Kara E. Comparative in vitro efficacies of various antipseudomonal antibiotics based catheter lock solutions on eradication of Pseudomonas aeruginosa biofilms. J Chemother. 2016; 28(1): 20-4. https://doi.org/10.1179/1973947814Y.0000000212.11
19. 19. Tudorache B, Lupulescu R, Dutan I, Sarbulescu A. Assessment of various psychopharmacological combinations in the treatment of presenile and senile primary degenerative dementia. Rom J Neurol Psychiatry. 1990; 28(4): 277-94.
20. 20. Volz HP, Hehnke U, Hauke W. Improvement in quality of life in the elderly. Results of a placebo-controlled study on the efficacy and tolerability of lecithin fluid in patients with impaired cognitive functions. MMW Fortschr Med. 2014; 12-146(Suppl 3-4): 99-106.
21. 21. Weintraub S, Mesulan MM, Auty R, Baratz R, Cholakos BN, Kapust L, et al. Lecithin in the treatment of Alzheimer's disease. Arch Neurol. 1983; 40(8): 527-8.
22. 22. Wu Y, Wang T. Soybean lecithin fractionation and functionality. JAOCS. 2003; 80(4): 319-26.
23. 23. Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter related sepsis. J Antimicrob Chemother. 2003; 51(4): 849-55. https://doi.org/10.1093/jac/dkg179.
24. 24. Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combination of tigecycline and N-acetylcysteine reduces biofilm-embedded bacteria on vascular catheters. Antimicrob Agents Chemother. 2007; 51(4): 1556-68. doi: 10.1128/AAC.00893-06.